Athenex, Inc. (ATNX)
(Delayed Data from NSDQ)
$10.12 USD
+0.19 (1.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.12 USD
+0.19 (1.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of 2.17% and 21.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Athenex (ATNX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Athenex (ATNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of 0.00% and 22.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Athenex (ATNX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Athenex (ATNX) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Athenex (ATNX) shares rose nearly 7% in the last trading session, amid huge volumes.
Athenex Rallies on Positive Early Data on Psoriasis Candidate
by Zacks Equity Research
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
by Zacks Equity Research
Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
by Zacks Equity Research
Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.
Athenex Completes Enrollment Target for Breast Cancer Study
by Zacks Equity Research
Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.
Company News For Dec 13, 2018
by Zacks Equity Research
Companies In The News Are: AEO,PVTL,LOW,ATNX
Is Athenex (ATNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATNX) Outperforming Other Medical Stocks This Year?
Is Athenex (ATNX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ATNX) Outperforming Other Medical Stocks This Year?
4 Best Performing Biotech Stocks of June: More Room to Run?
by Indrajit Bandyopadhyay
Biotech industry experiences a turnaround in June. Here are four stocks riding the rally.
Top Ranked Momentum Stocks to Buy for June 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 19th: